Substance / Medication

Gamma hydroxybutyrate

Overview

Active Ingredient
oxybate
RxNorm CUI
2387302

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
A Qualitative Approach in Understanding Illness Perception and Treatment Needs in Patients with Gamma Hydroxybutyrate Use Disorder.
Beurmanjer Harmen, Asperslag Eva M, Oliemeulen Lisette et al. · Eur Addict Res · 2019
PMID: 31163444Observational
A New Psychoactive Substance, Gamma Hydroxybutyrate (GHB): A Case Report.
Bulut Hüseyin · Noro Psikiyatr Ars · 2019
PMID: 31523153Case ReportFull text (PMC)
Paroxysmal sympathetic surge associated with gamma hydroxybutyrate.
Reed Matthew J, Clegg Gareth R · Eur J Emerg Med · 2006
PMID: 16374249Case Report
Gamma hydroxybutyrate withdrawal in an orthopedic trauma patient.
Slagel Brad, Kingstone Edward, Bhalerao Shree · Can J Psychiatry · 2003
PMID: 12655920Case Report
Changes in the rates and characteristics of gamma hydroxybutyrate (GHB)-related death in Australia, 2001-2023.
Darke Shane, Duflou Johan, Chrzanowska Agata et al. · Drug Alcohol Rev · 2025
PMID: 39238184OtherFull text (PMC)
Effect of body refrigeration on the postmortem formation of gamma hydroxybutyrate in whole blood.
Charunyanont Yotvarit, Tubtimrattana Apinya, Tansrisawad Nat et al. · Forensic Sci Int · 2022
PMID: 35278788Other
Characteristics and circumstances of death related to gamma hydroxybutyrate (GHB).
Darke Shane, Peacock Amy, Duflou Johan et al. · Clin Toxicol (Phila) · 2020
PMID: 32068430Other
The discriminative stimulus effects of baclofen and gamma hydroxybutyrate in C57BL/6J mice.
Wilkerson Jenny L, Hiranita Takato, Koek Wouter et al. · Behav Pharmacol · 2022
PMID: 35947069PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
4-hydroxybutyrate (substance)
SNOMED CT
259470008
UMLS CUI
C0000503
RxNorm CUI
2387302

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.